MARKER THERAPEUTICS INC

MRKR represents Marker Therapeutics, a clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer and other diseases. Its programs include non-engineered T cell therapies designed to target multiple tumor-associated antigens. As a clinical-stage company, its progress depends heavily on research and development milestones rather than commercial product sales.

MRKR trades on the Nasdaq Capital Market under the ticker symbol MRKR. Nasdaq listing provides access to U.S. equity trading venues and requires the company to meet certain listing standards, including minimum share price and reporting requirements. Investors can typically trade MRKR through brokerage accounts that offer Nasdaq-listed securities.

Recent performance for MRKR depends on current market trading and company-specific news. For the latest price changes, volume, and short-term trends, refer to the live MRKR quote and performance data displayed on this page. These figures update regularly and reflect the most current available market information.

MRKR is a small-cap, clinical-stage biotechnology stock, a category that often experiences significant price volatility. Share prices can react sharply to clinical trial updates, financing announcements, regulatory news, and broad biotech market sentiment. Trading volume may also fluctuate, which can amplify price movements in either direction.

Because MRKR is a clinical-stage biotech company without meaningful product revenue, traditional valuation metrics like P/E ratios are often not useful. Investors may look at cash position, burn rate, pipeline progress, and comparable company valuations. The current market capitalization and relevant financial figures are available in the live MRKR data on this page.

Key risks for MRKR include clinical trial failure, regulatory delays, reliance on future financing, and competition in immunotherapy. As a small-cap biotech, it may have limited resources and no approved products, so setbacks can materially affect its value. Investor attention often centers on pipeline updates, cash runway, and dilution risk.